5th International Myeloma Workshop

„Multiple Myeloma: Hot Topics in in 2020"

Friday, March 27th
Lecture Hall, Hotel Rebstock, Würzburg

5th International Myeloma Workshop

12.00	**Welcome address** Hermann Einsele
Session 1:	**New insights into the pathogenesis of MM**
12.15 - 12.30	**Lessons from the myeloma genome project** Gareth Morgan, NY, USA (confirmed) *Introduced by Leo Rasche, Würzburg*
12.30 - 12.45	**Who drives the disease in MM? MYC, microRNAs, or the microbiome?** Leif Bergsagel, Scottsdale, AZ, USA
12.45 - 13.15	**Clone wars in myeloma evolution: Darwin or Big Bang?** Martin Kaiser, London, UK
13.15 - 13.30	**The myeloma microenvironment: ignored or overrated?** Madhav V. Dhodapkar, Atlanta, USA
	Discussion
	- **LUNCH** -
Session 2:	**High risk Multiple Myeloma**
14.00 - 14.15	**Genetics associated with High-Risk disease** Herve Avet-Loseau, Tolouse, FR
14.15 - 14.30	**Double hit myelomas** Brian Walker, Indiana, USA
14.15 - 14.30	**The role of imaging to detect high risk disease** Elena Zamagni, Bologna, IT
14.30 - 14.45	**How I define and treat high-risk multiple myeloma** Frits van Rhee, UAMS, Little Rock
	Discussion

- **COFFEE BREAK** -

Session 3:	**Translational research**
15.30 – 15:45	**From mice to men: What can we learn from murine MM models?** Marta Chesi, Scotsdale, USA
15.45 - 16.00	**Carfilzomib: Low-dose – standard dose – or high dose?** Christoph Driessen, St. Gallen
16.00 - 16.45	**Immunomodulatory drugs: CRBLN inhibition and beyond** Florian Bassermann, München, GER
16.45 - 17.00	**Novel drugs on the horizon** Charlotte Pawlyn, London, UK
	Discussion
Session 4:	**Satellite Symposium**
17.00 – 18.00	
19.30	**Welcome reception:**

Saturday, March 28th 2020
Würzburg Residence Conference Center

09.00	**Welcome, introduction** Hermann Einsele
Session 1:	**One size fits all vs. Personalized medicine in myeloma**
09.15 - 09.30	**Multiple Myelomas – introducing tumor heterogeneity in MM** Niels Weinhold, Heidelberg, GER
09.30 - 09.45	**MM Precision Medicine at the Mayo clinic – today and tomorrow** Keith Stewart, USA (confirmed) *Introduced by Martin Kortüm, Würzburg*
09.45 - 10.00	**Targeted, immune, and epigenetic therapies MM- the Mount Sinai approach** Samir Parekh, NY, USA
10.00 - 10.15	**Targeting BRAF in MM** Marc Raab, Heidelberg, GER
10:15 - 10.30	**Venetoclax: The first targeted therapy for MM?** Cyrille Tozeau, Nantes, FR
	Discussion
	COFFEE BREAK -
Session 2:	**Minimal Residual Disease**
11.00 - 11.15	**Clinical case presentations on the issue MRD** *NN, Würzburg*

11.15 - 11.30	**How do we measure MRD in MM? NGS, NGF, and Imaging?** Joaquin Martinez Lopez, Madrid, ESP
11.30 - 11.45	**MRD triggered treatment decisions: Today and tomorrow** Faith Davies, NY, USA
	Discussion
Session 3:	**Debate: Should we treat SLiMM CRAB positive asymptomatic myeloma?**
11.45 - 12.00	**Yes** Wolfgang Willenbacher, Innsbruck, A
12.00 – 12:15	**No** Heinz Ludwig, Vienna, A
	Discussion
	LUNCH -
Session 4:	**Novel immunotherapies for MM**
13.15 -13.30	**BCMA CARs on the road to cure?** Nina Shah, LA, USA
13.30 - 13.45	**CARs addressing alternative targets** Michael Hudecek, Würzburg
13.45 – 14.00	**MM BiTE – The Würzburg experience** Hermann Einsele, Würzburg
14.00 - 14.15	**Antibody drug conjugates** Suzanne Trudel, Toronto, Canada
14.15 – 14.30	**CD38 directed therapies** Niels Van de Donk, Amsterdam
	Closing remark, farewell reception Hermann Einsele
Session 5 14.45- 16.00	**Satellite Symposium:** **Current protocols and future plans of the GMMG and DSMM**

Medizinische Klinik
und Poliklinik II